About 20 years ago, the landmark study of gefitinib over carboplatin‐paclitaxel revolutionized the treatment of NSCLC patients, and the IPASS study demonstrated that patients with EGFR driver mutations benefitted most from this tyrosine kinase inhibitor (TKI)–based therapy.37 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.